Additional in vivo studies to assess activity of B7H3.CAR EBVSTs against B7-H3–expressing gastric cancer, TNBC, NSCLC and a second colorectal cancer xenografts demonstrated similarly promising efficacy and tolerability outcomes (Supplementary Fig. S4C). The gene discussed is CD276; the disease is gastric cancer.